A fast method for the quantification of bortezomib in serum and rat nervous tissue by liquid chromatography tandem mass spectrometry
Authors:
- Jonas Moritz HuhnJHJonas Moritz Huhn
- Mona HashemianMHMona Hashemian
- Martina KinzigMKMartina Kinzig
- Elisabete Bóf RamosERElisabete Bóf Ramos
- Fritz SörgelFSFritz Sörgel
- Claudia SommerCSClaudia Sommer
- Oliver Scherf-ClavelOSOliver Scherf-Clavel
Open Access
- 29 July 2026
- journal article
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 281
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Development and validation of an UPLC–MS/MS method for simultaneous determination of meropenem and its open-ring metabolite in human serum and cerebrospinal fluid with application to clinical samplesJournal of Pharmaceutical and Biomedical Analysis, 2026
- Bortezomib in cancer therapy: Mechanisms, side effects, and future proteasome inhibitorsLife Sciences, 2024
- Simultaneous estimation of paclitaxel and bortezomib via LC-MS/MS: pharmaceutical and pharmacokinetic applicationsNanomedicine, 2024
- Population-based meta-analysis of bortezomib exposure–response relationships in multiple myeloma patientsJournal of Pharmacokinetics and Pharmacodynamics, 2020
- Clinical Pharmacokinetics and Pharmacodynamics of BortezomibClinical Pharmacokinetics, 2018
- LC–MS/MS method for simultaneous determination of thalidomide, lenalidomide, cyclophosphamide, bortezomib, dexamethasone and adriamycin in serum of multiple myeloma patientsJournal of Chromatography B, 2016
- Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MSJournal of Chromatography B, 2013
- Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myelomaCancer Chemotherapy and Pharmacology, 2010
- Elucidation of potential bortezomib response markers in mutliple myeloma patientsJournal of Pharmaceutical and Biomedical Analysis, 2009
- The development of proteasome inhibitors as anticancer drugsCancer Cell, 2004